Pharma Roundup: NYC Wants Biotech, Amgen Predicts Blockbusters, and More

New York City wants biotech -- The city is investing more than $700 million in biotech facilities, hoping to lure companies from California and Massachusetts, the current hubs of bitoech activity. More than one million square feet of office and lab space will open by 2010. [Source: FierceBiotech]

Amgen predicts blockbusters -- CEO Kevin Sharer expects big sales for Sensipar and denosumab. [Source: PharmaGossip]

Pharma execs no longer cutting costs -- Ernst & Young has released a survey which suggests cost-cutting is no longer a top priority among pharma executives. Instead, they claim they need to hurry drugs along to market and fix the research process first. [Source: Pharmalot]